Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10(2):63–89

Article  PubMed  PubMed Central  Google Scholar 

Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A et al (2019) Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis 22(1):24–38

Article  PubMed  Google Scholar 

Watson PA, Arora VK, Sawyers CL (2015) Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 15(12):701–711

Article  PubMed  PubMed Central  Google Scholar 

Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S et al (2009) Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 115(15):3437–3445

Article  PubMed  Google Scholar 

Schalken J, Fitzpatrick JM (2016) Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. BJU Int 117(2):215–225

Article  PubMed  Google Scholar 

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(4):352–360

Article  PubMed  Google Scholar 

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995–2005

Article  PubMed  PubMed Central  Google Scholar 

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187–1197

Article  PubMed  Google Scholar 

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424–433

Article  PubMed  PubMed Central  Google Scholar 

Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN et al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378(15):1408–1418

Article  PubMed  Google Scholar 

Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U et al (2018) Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 378(26):2465–2474

Article  PubMed  PubMed Central  Google Scholar 

Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S et al (2019) Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 380(13):1235–1246

Article  PubMed  Google Scholar 

Chi KN, Chowdhury S, Bjartell A, Chung BH, de Pereira Santana Gomes AJ, Given R et al (2021) Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 39(20):2294–2303

Article  PubMed  Google Scholar 

Chi KN, Agarwal N, Bjartell A, Chung BH, de Pereira Santana Gomes AJ, Given R et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381(1):13–24

Article  PubMed  Google Scholar 

Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF et al (2020) Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 382(23):2197–2206

Article  PubMed  Google Scholar 

Australian Bureau of Statistics (2025) Population clock and pyramid. https://www.abs.gov.au/statistics/people/population/population-clock-pyramid.

Department of Health Disability and Ageing (2026) Fees, Patient Contributions and Safety Net Thresholds. https://www.pbs.gov.au/info/healthpro/explanatory-notes/front/fee?utm_source=chatgpt.com.

Pockros B, Shabet C, Stensland K, Herrel L (2023) Out-of-pocket costs for prostate cancer medications substantially vary by Medicare part D plan: an online tool presents an opportunity to mitigate financial toxicity. Urol Pract 10(5):467–475

Article  PubMed  PubMed Central  Google Scholar 

Gupta A, Antonarakis ES, Blaes AH, Booth CM, Dusetzina SB (2022) Evaluation of Medicare coverage and estimated out-of-pocket costs for generic abiraterone products. JAMA Netw Open 5(9):e2231475

Article  PubMed  PubMed Central  Google Scholar 

Bencina G, Petrova E, Sonmez D, Matos Pereira S, Dimitriadis I, Salomonsson S (2023) HTA and reimbursement status of metastatic hormone‑sensitive prostate cancer, non-metastatic castration-resistant prostate cancer, and metastatic castration-resistant prostate cancer treatments in Europe: a patient access landscape review. J Health Econ Outcomes Res 10(1):102–110

Article  PubMed  PubMed Central  Google Scholar 

Chang SL, Liao JC, Shinghal R (2009) Decreasing use of luteinizing hormone-releasing hormone agonists in the United States is independent of reimbursement changes: a Medicare and Veterans Health Administration claims analysis. J Urol 182(1):255–261

Article  PubMed  Google Scholar 

Goebell PJ, Raina R, Chen S, Rege S, Shah R, Grossman JP et al (2024) Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia. Future Oncol 20(14):903–918

Article  PubMed  Google Scholar 

Fontes MS, Schutz FA, de Almeida Luz M, Bomfim G, Saturnino LTM, Goncalves SC et al (2022) Treatment patterns among patients with advanced prostate cancer in Brazil: an analysis of a private healthcare system database. World J Oncol 13(6):350–358

Article  PubMed  PubMed Central  Google Scholar 

Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A et al (2019) ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 37(32):2974–2986

Article  PubMed  PubMed Central  Google Scholar 

Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED et al (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 386(12):1132–1142

Article  PubMed  PubMed Central  Google Scholar 

Zhou B, Raval AD, Zhang Y, Korn MJ, Sambamoorthi N, Rasu R et al (2025) Treatment landscape for older men with metastatic hormone-sensitive prostate cancer in the United States. Cancer Med 14(17):e71176

Article  PubMed  PubMed Central  Google Scholar 

Litvin V, Aprikian AG, Dragomir A (2025) Cost-effectiveness analysis of contemporary advanced prostate cancer treatment sequences. Curr Oncol. https://doi.org/10.3390/curroncol32040240

Article  PubMed  PubMed Central  Google Scholar 

Freedland SJ, Hong A, El-Chaar N, De Hoedt AM, Kim J, Evans C et al (2025) Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancer. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-025-01000-8

Article  PubMed  PubMed Central  Google Scholar 

Bolek H, Yazgan SC, Yekeduz E, Kaymakcalan MD, McKay RR, Gillessen S et al (2024) Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer. ESMO Open 9(11):103736

Article  PubMed  PubMed Central  Google Scholar 

Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ et al (2017) Neoadjuvant enzalutamide prior to prostatectomy. Clin Cancer Res 23(9):2169–2176

Article  PubMed  Google Scholar 

Xie J, Guo H, Dong B, Chen W, Jin C, Xu Q et al (2024) Olaparib combined with abiraterone versus olaparib monotherapy for patients with metastatic castration-resistant prostate cancer progressing after abiraterone and harboring DNA damage repair deficiency: a multicenter real-world study. Eur Urol Oncol 7(5):1088–1096

Article  PubMed  Google Scholar 

Luo Q, Yu XQ, Kahn C, Egger S, Patel MI, Grogan PB et al (2022) Changes in prostate cancer incidence, mortality and survival in relation to prostate specific antigen testing in New South Wales, Australia. Cancer Epidemiol 78:102159

Article  PubMed  Google Scholar